Macrommune Therapeutics raises £20k for biotech research

The Sittingbourne-based enterprise, Macrommune Therapeutics Ltd, has closed a funding round valued at £20k. It operates within the biotechnology sector, focusing on experimental development.

The firm’s scientific activities include bioinformatics and biology research. Its technical remit extends to the engineering of cell and tissue cultures, alongside specialized work in nanobiotechnology.

The business also examines DNA and RNA, as well as the development of gene and RNA vectors. Its investigative scope further encompasses the study of proteins and various other molecules.

The startup was incorporated in May 2026, with formal documentation for this share allotment filed in September 2026.